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Introduction {#sec1}
============

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by a pre-mutation of 55 to 200 CGG repeats in the 5′ untranslated region (UTR) of the *fragile X mental retardation 1* (*FMR1*) gene ([@bib19]). The carrier prevalence of the CGG pre-mutation is approximately 1 of ∼200 females and ∼450 males, but due to incomplete penetrance, it is estimated that 1 in 3,000 men older than 50 years will develop FXTAS ([@bib27], [@bib52]). The clinical features of FXTAS include progressive intention tremor and gait ataxia, frequently accompanied by progressive cognitive decline, parkinsonism, peripheral neuropathy, and autonomic dysfunctions ([@bib26]). Principal neuropathologies of FXTAS include mild brain atrophy and white matter lesions with the presence of ubiquitin-positive nuclear neuronal and astrocytic inclusions ([@bib17]). In contrast to fragile X syndrome, where expanded full mutation alleles (\>200 CGG repeats) result in hypermethylation and silencing of the *FMR1* gene, FXTAS carriers of pre-mutation expanded alleles (55--200 CGG repeats) present increased levels of *FMR1* mRNA but slightly reduced expression of the protein encoded by *FMR1*, FMRP ([@bib50], [@bib51], [@bib34]).

Because FXTAS is not observed in fragile X patients with fully silenced *FMR1* alleles, a pathogenic mechanism based on expression of mutant *FMR1* mRNAs containing expanded CGG repeats has been proposed ([@bib18]). In support of this hypothesis, multiple studies have demonstrated adverse consequences of expressing RNA containing expanded CGG repeats in cell, fly, and mouse models ([@bib54], [@bib29], [@bib1], [@bib20], [@bib11], [@bib22], [@bib23]). However, how *FMR1* mRNA containing expanded CGG repeats is pathogenic is unclear. A first proposed model is that FXTAS results from a toxic RNA gain-of-function mechanism in which mutant RNA containing expanded CGG repeats sequesters specific RNA binding proteins, resulting in neuronal cell dysfunctions ([@bib25], [@bib48], [@bib30], [@bib45], [@bib46]). A second proposed mechanism is that FXTAS is caused by repeat-associated non-AUG (RAN) translation of the expanded CGG repeats into polyalanine- and polyglycine-containing proteins named FMRpolyA and FMRpolyG ([@bib53]). Ranum and colleagues originally demonstrated that expanded CAG repeats can be translated in all three frames in the absence of any AUG initiation codon ([@bib57]). Subsequently, RAN translation was described and proposed as a causative mechanism in various inherited microsatellite neurodegenerative disorders (reviewed in [@bib8]), including FXTAS ([@bib53], [@bib33]). However, the mechanism and the pathological consequences of translating expanded CGG repeats are not fully understood. Specifically, which pathological mechanism (RNA gain-of-function or RAN translation) drives FXTAS pathogenesis is a crucial question.

Here we find that translation of expanded CGG repeats occurs predominantly in the glycine frame through initiation at a near-cognate ACG codon located upstream of the expanded CGG repeats. Importantly, transgenic mice expressing both CGG RNA repeats and the polyglycine protein (FMRpolyG mouse), but not mice expressing only the mutant RNA containing expanded CGG repeats (CGG RNA mouse), exhibit inclusion formation, motor phenotypes, and reduced lifespan. FMRpolyG interacts with LAP2β, a protein essential to anchoring lamin proteins to the inner nuclear membrane, and overexpression of LAP2β rescues neuronal cell death induced by expression of FMRpolyG. Overall, these results suggest that translation of expanded CGG repeats into FMRpolyG, which alters nuclear lamina, may contribute to FXTAS.

Results {#sec2}
=======

Translation of Expanded CGG Repeats Initiates at an Upstream Near-Cognate Codon {#sec2.1}
-------------------------------------------------------------------------------

To confirm previous observations of translation of expanded CGG repeats in the absence of an AUG start codon ([@bib53], [@bib33]), we cloned 100 CGG repeats embedded within the natural human 5′ UTR of *FMR1*, which was fused to the GFP deleted of its ATG and in all three possible frames ([Figure S1](#mmc1){ref-type="supplementary-material"}A). These frames were named according to the polypeptide potentially encoded by the expanded CGG repeats---namely, glycine, alanine, and arginine. Cell transfection and immunoblotting against GFP confirm previous data ([@bib53], [@bib33]) and demonstrate that the 5′ UTR of *FMR1* with expanded CGG repeats allows translation of a GFP protein with an ∼12 kDa N-terminal extension corresponding to the expanded CGG repeats translated into the glycine frame ([Figure 1](#fig1){ref-type="fig"}A and [Figure S1](#mmc1){ref-type="supplementary-material"}B). In contrast, we observed no translation when the *FMR1* sequence located upstream of the repeats was deleted ([Figure 1](#fig1){ref-type="fig"}A and [Figure S1](#mmc1){ref-type="supplementary-material"}B). Serial deletions confirmed that a short *FMR1* sequence located upstream of the CGG repeats was required for FMRpolyG translation ([Figure 1](#fig1){ref-type="fig"}B). Treatment with Lysostaphin, a polyglycine endopeptidase, confirmed that expanded CGG repeats are translated into a polyglycine-containing protein ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

To further characterize the initiation site of expanded CGG repeat translation, we immunoprecipitated FMRpolyG and determined its N-terminal sequence by proteomic analysis after trypsin digestion. LC-MS/MS spectra revealed initiation to an ACG near-cognate codon located 32 nucleotides upstream of the CGG expansion ([Figure 1](#fig1){ref-type="fig"}C). To exclude any bias of digestion, we repeated this experiment with a construct containing a mutation in which a lysine (sensitive to the LysC enzyme) is present upstream of the expanded CGG repeats, but the remaining sequence, notably the ACG codon, is untouched. Proteomic analysis of FMRpolyG after LysC digestion confirmed that FMRpolyG translation initiates at the ACG near-cognate codon ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Of interest, proteomic analysis also revealed that the initial amino acid of FMRpolyG is a methionine, suggesting that the ACG codon is decoded by an initiator Met-tRNA despite imperfect match ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}D). This ACG near-cognate codon is embedded in a putative Kozac consensus sequence that is conserved among multiple species ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Translation initiation at the ACG near-cognate codon is predicted to result in a small FMRpolyG protein composed of a short, 12-amino-acid N terminus, a central glycine stretch with a length that corresponds to the number of expanded CGG repeats, and a C terminus of 42 amino acids with no predicted structure or homology ([Figure 1](#fig1){ref-type="fig"}D). Thus, according to the number of CGG repeats, FMRpolyG may range from 7 kDa in control individuals with 30 CGG repeats to ∼15 kDa in carriers of pre-mutation with 150 CGG repeats.

A Minimum of 60 to 70 Expanded CGG Repeats Is Required to Detect FMRpolyG {#sec2.2}
-------------------------------------------------------------------------

Upstream ORFs (uORFs) are short open reading frames that are located in the 5′ UTR of mRNAs upstream of the main ORF. Due to the 5′ to 3′ scanning ribosome process, and in absence of ribosome re-initiation, the translation of a uORF generally impairs translation of the downstream main ORF. To avoid complete translation inhibition, uORFs typically start by an AUG or a near-cognate codon (GUG, CUG, UUG, ACG, etc.) embedded in a poor Kozac consensus sequence that enables leaky ribosomal scanning and hence translation initiation at the downstream main ORF (reviewed in [@bib49]). To test the presence of a putative uORF encompassing the CGG repeats in *FMR1*, we cloned various lengths of CGG expansion within the human 5′ UTR of *FMR1* fused in the glycine frame with a small FLAG tag (eight amino acids, ∼1 kDa). Immunoblotting revealed that expression of FMRpolyG-FLAG is detected only with expanded CGG repeats over 60 to 70 CGG repeats ([Figure 2](#fig2){ref-type="fig"}A), the threshold over which pre-mutation carriers are at risk of developing FXTAS. Fusion of expanded CGG repeats in the glycine frame to the GFP (25 kDa) confirmed that translation occurred with expanded CGG repeats of various lengths (70 to 100 repeats), characteristic of pre-mutation carriers ([Figure 2](#fig2){ref-type="fig"}B). However, FMRpolyG-GFP was also translated with short stretches of CGG repeats (30) found in control individuals or even without any CGG repeats ([Figure 2](#fig2){ref-type="fig"}B). These results suggest that translation initiation occurs at the ACG near-cognate codon independently of the CGG repeats but that expansion over 70 repeats is important for detection of FMRpolyG. This is characteristic of short upstream ORFs that are generally translated into small and most often undetectable peptides but which are detected when fused with large tags, resulting in stable and detectable proteins ([@bib3]).

Next, we noted that FMRpolyG and FMRP ORFs are in different frames, with the last 20 amino acids of FMRpolyG naturally overlapping the FMRP N terminus ([Figure 1](#fig1){ref-type="fig"}D). Thus, translation of the FMRpolyG uORF may potentially impair ribosomal re-initiation to the downstream FMRP ORF. To test that hypothesis, we fused the 5′ UTR of *FMR1* to a FLAG tag in the glycine frame and also fused the downstream FMRP ORF in frame with the GFP ([Figure 2](#fig2){ref-type="fig"}C). This construct expresses the FLAG-tagged FMRpolyG uORF or the downstream GFP-tagged FMRP main ORF ([Figure 2](#fig2){ref-type="fig"}C), suggesting that translation initiation occurs either at the FMRpolyG ACG near-cognate codon or at the FMRP ATG codon. Deletion of the 5′ UTR sequence containing the ACG near-cognate initiation codon abolished expression of the FLAG-tagged FMRpolyG uORF but enhanced translation of the downstream GFP-tagged FMRP ORF ([Figure 2](#fig2){ref-type="fig"}C). In contrast, mutation of the ACG near-cognate codon into a cognate AUG initiation codon predictably enhanced translation of the FLAG-tagged FMRpolyG uORF, but abolished expression of the downstream, GFP-tagged FMRP ORF ([Figure 2](#fig2){ref-type="fig"}C).

To confirm that FMRpolyG is encoded by an ORF initiating upstream of the CGG repeats, we developed an antibody directed against the 12 amino acids located upstream of the glycine repeats ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Immunofluorescence revealed the presence of FMRpolyG N terminus in brain sections of FXTAS patients, but not in age-matched control individuals ([Figure 2](#fig2){ref-type="fig"}D). FMRpolyG N terminus is detected as single nuclear inclusions that co-localize with ubiquitin, which is consistent with the known histopathological features of FXTAS ([@bib17]). We confirmed these results by immunoblotting and found that, according to the size of the CGG expansion, FMRpolyG was detected as a 10- to 14-kDa protein in the insoluble fraction of brain lysate of FXTAS individuals ([Figure 2](#fig2){ref-type="fig"}E). The poor quality of the immunoblotting is probably due to the propensity of this glycine-rich protein to aggregate. To ensure that translation successfully passes across the expanded CGG repeats, we also developed an antibody against the amino acids located downstream of the glycine repeats ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Consistent with previous analyses ([@bib53], [@bib5]), immunofluorescence confirmed presence of FMRpolyG C terminus in brain sections of FXTAS patients, but not in age-matched control individuals ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Finally, translation of expanded CGG repeats into a polyalanine-containing protein was reported previously ([@bib53], [@bib33]). We developed an antibody against the putative C-terminal part of this protein ([Figure S2](#mmc1){ref-type="supplementary-material"}C), but observed no or very little FMRpolyA in individuals with FXTAS ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic in Mice {#sec2.3}
-----------------------------------------------------------------------

The presence of both CGG RNA aggregates, which can titrate out RNA binding proteins, and FMRpolyG--positive inclusions in individuals with FXTAS raises the question of which pathogenic mechanism is driving neuronal degeneration in this disease. To differentiate between these two hypotheses, we developed two transgenic mouse models. The first one contains the full human 5′ UTR of *FMR1* with expanded 99 CGG repeats that express both CGG RNA and FMRpolyG protein, while the second mouse model also expresses 99 CGG repeats, but the non-canonical ACG initiation codon and surrounding 5′ UTR sequence are deleted so it only expresses the CGG RNA ([Figure 3](#fig3){ref-type="fig"}A). Both constructs are driven by a chimeric CAG promoter inserted within the neutral *Rosa26* locus and under repression of a loxP-polyadeneylation cassette ([Figure 3](#fig3){ref-type="fig"}A).

Deletion of the loxP cassette using a ubiquitously and embryonically expressed Cre recombinase led to high expression of transgene RNA throughout the brain, heart, and liver, with lower expression in skeletal muscle, kidneys, and other organs ([Figure 3](#fig3){ref-type="fig"}B). Importantly, transgene RNA expression was similar in bigenic CMV-cre mice with either the full or mutant *FMR1* 5′ UTR ([Figure 3](#fig3){ref-type="fig"}B). However, we found no or only very rare CGG RNA foci in brain sections of full or mutant *FMR1* 5′ UTR transgenic mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). This is consistent with the rare occurrence of CGG RNA aggregates in other transgenic mouse models expressing expanded CGG repeats ([@bib45]). Concerning the FMRpolyG protein, immunohistochemistry assays demonstrated expression and accumulation of nuclear aggregates of FMRpolyG in brain sections from the full 5′ UTR *FMR1* transgenic mice, but not in the mutant 5′ UTR mice ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C). These results confirm in mouse models that translation of the CGG repeats in the glycine frame requires the presence of an upstream *FMR1* sequence. As observed in brain samples of individuals with FXTAS, aggregates of FMRpolyG in mice co-localized with ubiquitinated inclusions ([Figure 3](#fig3){ref-type="fig"}D). Nuclear aggregates of FMRpolyG accumulated over time, with the largest burden of inclusions occurring within the hypothalamus, mirroring transgene RNA expression ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Some rare aggregates of FMRpolyG were found in other tissues than brain, which is reminiscent of reported FMRpolyG aggregates in non-CNS tissues in FXTAS patients ([@bib5]). In contrast, we did not observe aggregates of FMRpolyA in the full or mutant 5′ UTR mice ([Figure S3](#mmc1){ref-type="supplementary-material"}E).

To determine the consequences of FMRpolyG production in mice, we conducted a series of behavioral and locomotor assays on both mouse lines. Mice with the full 5′ UTR of *FMR1* develop obesity at 6 months of age. Therefore, behavioral tests were performed at 3 months of age when weight is identical between full and mutant *FMR1* 5′ UTR transgenic mice. Importantly, we observed that only mice with both the full 5′ UTR sequence of *FMR1* and expression of the FMRpolyG protein present locomotor deficiency ([Movies S1](#mmc2){ref-type="supplementary-material"} and [S2)](#mmc3){ref-type="supplementary-material"}, with increased falling from rotarod ([Figure 3](#fig3){ref-type="fig"}E), decreased ability of traction from the hind limbs ([Figure 3](#fig3){ref-type="fig"}F), decreased grip strength ([Figure 3](#fig3){ref-type="fig"}G), and a decreased number of rears in open field observation ([Figure 3](#fig3){ref-type="fig"}H). At 6 months of age, mice with the full 5′ UTR of *FMR1* lose mobility and develop obesity, while mice with the mutant 5′ UTR that express only the CGG RNA remain normal ([Figure 3](#fig3){ref-type="fig"}I). We did not observe massive neuronal cell death, but found some loss of Purkinje cells in mice with the full 5′ UTR of *FMR1* compared to mutant 5′ UTR mice ([Figures 3](#fig3){ref-type="fig"}J and [S3](#mmc1){ref-type="supplementary-material"}F). Furthermore, Iba1 and Gfap staining were mildly increased in brain sections of mice with the full 5′ UTR of *FMR1* compared to mutant 5′ UTR mice, suggesting some increased neuroinflammation in FMRpolyG-expressing animals ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Finally, expression of FMRpolyG is deleterious, as mice expressing the full 5′ UTR of *FMR1* die at around 10 months, while mutant *FMR1* 5′ UTR mice exhibit normal longevity and are indistinguishable from control mice ([Figure 3](#fig3){ref-type="fig"}K).

To assess the tissue origin of these phenotypes, we next analyzed offspring of full 5′ UTR transgenic mice crossed with Nestin-cre mice, which express the Cre recombinase in precursors of neurons and glia cells around E10.5 ([Figure 4](#fig4){ref-type="fig"}A). Quantitative RT-PCR revealed high expression of expanded CGG RNA only in mouse brain of the double transgenic Nestin-cre/full 5′ UTR *FMR1* mice, confirming the specificity of the Nestin promoter ([Figure 4](#fig4){ref-type="fig"}B). Immunohistochemistry indicated expression and accumulation of nuclear aggregates of FMRpolyG in brain sections of these bigenic mice, but not in control, non-transgenic animals ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}A). Importantly, locomotor testing at 3 months of age revealed increased falling from rotarod compared to control, non-transgenic mice ([Figure 4](#fig4){ref-type="fig"}D). Histopathological analyzes revealed some Purkinje cell loss ([Figure 4](#fig4){ref-type="fig"}E) and evidence of neuroinflammation ([Figure 4](#fig4){ref-type="fig"}F) in 9- to 10-month-old Nestin-cre/full 5′ UTR *FMR1* mice compared to control animals. Interestingly, mice expressing FMRpolyG only in the brain developed obesity ([Figure 4](#fig4){ref-type="fig"}G) and exhibited reduced longevity ([Figure 4](#fig4){ref-type="fig"}H), similar to the CMV-cre/full 5′ UTR *FMR1* mice. The obesity developed by these mice may originate from dysfunction of the hypothalamus, as this area is the one expressing the most and the earliest FMRpolyG. In support of that hypothesis, RT-qPCR indicated that expression of the leptin receptor, which is essential to regulate energy balance by inhibiting hunger, was decreased in the hypothalamic area of these mice ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

The 5′ UTR Sequence of *FMR1* Impairs Formation of Expanded CGG-Repeat RNA Foci {#sec2.4}
-------------------------------------------------------------------------------

The absence of RNA foci of expanded CGG repeats in full and mutant 5′ UTR *FMR1* mice is puzzling, as FXTAS is proposed to result from nuclear accumulation of mutant CGG RNA that would sequester various RNA binding proteins. Thus, we tested whether transfection of expanded CGG repeats embedded in their natural *FMR1* 5′ UTR sequence would form any RNA foci in mouse neuronal cell cultures. As positive control, we used a construct expressing expanded CGG repeats without the surrounding *FMR1* sequence that was previously shown to form RNA foci in transfected cells ([@bib45], [@bib46]; [Figure S4](#mmc1){ref-type="supplementary-material"}C). RNA FISH assays indicated that expanded CGG repeats embedded in the 5′ UTR of *FMR1* formed rare RNA foci compared to the expanded CGG repeats without the surrounding *FMR1* sequence ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Furthermore, RT-PCR performed on nuclear and cytoplasmic fractions indicated that most of the RNAs containing expanded CGG repeats embedded within the 5′ UTR of *FMR1* are exported from the nucleus to the cytoplasm ([Figure S4](#mmc1){ref-type="supplementary-material"}E). In contrast, expanded CGG-repeat RNAs without the *FMR1* sequence are largely retained within cell nuclei ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Both constructs present similar plasmid backbones with strong polyadenylation signals ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These results highlight the nuclear retention bias induced by using artificial constructs in which microsatellite repeats are separated from their natural sequence context. Importantly, these data also indicate that CGG expanded repeats embedded in their natural *FMR1* sequence are exported into the cytoplasm and thus available for translation into FMRpolyG.

Expression of FMRpolyG Is Toxic for Neuronal Cells {#sec2.5}
--------------------------------------------------

Next, we investigated by which mechanisms the FMRpolyG protein may elicit neuronal cell dysfunction. Immunofluorescence assays indicated that FMRpolyG first accumulates in the cytoplasm, where it forms aggregates. These aggregates then migrate and form an inclusion within the cell nucleus in primary mouse-embryonic neuronal cultures ([Figure 5](#fig5){ref-type="fig"}A). Similar results were observed in HEK293 cells and when a smaller FLAG epitope tag was used instead of GFP ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Furthermore, immunoblotting indicated that FMRpolyG progressively accumulates in the insoluble fraction of transfected cell lysates, which is consistent with its propensity to form aggregates ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

To identify the sequence driving FMRpolyG aggregation, we cloned various deletion mutants of FMRpolyG expressing either its N terminus with the glycine repeats or its C terminus in isolation. To obtain comparable expression, all mutant constructs were driven by an ATG ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Expression of the full-length FMRpolyG protein in primary cultures of E18 mouse cortical neurons leads to nuclear aggregates associated with cell death ([Figure 5](#fig5){ref-type="fig"}B). Expression of the polyglycine stretch in isolation, with the C terminus of FMRpolyG deleted, was sufficient to elicit aggregation but was not overtly toxic. In contrast, expression of GFP fused to the 42 amino acids constituting the C terminus of FMRpolyG caused neuronal cell death without forming nuclear aggregates ([Figure 5](#fig5){ref-type="fig"}B; [Movies S3](#mmc4){ref-type="supplementary-material"}, [S4](#mmc5){ref-type="supplementary-material"}, [S5](#mmc6){ref-type="supplementary-material"}, and [S6](#mmc7){ref-type="supplementary-material"}). Similar results were observed in Neuro2A cells ([Figure S5](#mmc1){ref-type="supplementary-material"}E) and when the GFP tag was replaced by the smaller FLAG tag ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

To confirm these results in an animal model and test the toxicity of FMRpolyG on a longer time period, we developed *Drosophila* transgenic lines expressing either the full FMRpolyG protein or the polyglycine stretch in isolation under a *UAS* promoter. Toxicity was assessed by two separate assays. First, *UAS* FMRpolyG-GFP and *UAS* polyG ΔCter-GFP flies, both expressed under an ATG initiator codon, were crossed with an *Act5c-Gal4* driver line, which leads to ubiquitous expression of the transgene during development. Total progeny carrying either the transgenes or a balancer chromosome were then quantified over three independent crosses. Importantly, expression of the full FMRpolyG was toxic and reduced progeny eclosion by half, while the eclosion rate was only slightly reduced in flies expressing the polyglycine stretch in isolation ([Figure 5](#fig5){ref-type="fig"}C). To exclude any potential bias due to random insertion effects, we generated and analyzed various independent lines expressing either FMRpolyG or its polyglycine stretch. As control, quantitative RT-PCR showed similar expression of the FMRpolyG or polyglycine transgenes ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Importantly, all lines expressing FMRpolyG-GFP showed reduced viability compared to GFP controls. In contrast, the lines expressing the glycine repeats in isolation consistently exhibited a milder phenotype ([Figure S5](#mmc1){ref-type="supplementary-material"}H).

As a second measure of FMRpolyG toxicity, we crossed these same transgenic fly lines to a *Tubulin-Gal4* Geneswitch driver, which expression is induced upon addition of mifepristone (RU-486). As a control, adult transgenic flies reared off of RU-486 drug exhibited no differences in viability from control flies, indicating that insertion of the FMRpolyG or polyglycine transgenes had no deleterious effect. In contrast, transgenic flies fed with RU-486, activating ubiquitous transgene expression, showed a decrease in viability over time for FMRpolyG expressing flies ([Figure 5](#fig5){ref-type="fig"}D). Adult *Drosophila* expressing the polyglycine stretch alone also presented a decrease in viability ([Figure 5](#fig5){ref-type="fig"}D); however, their survival was significantly prolonged compared to flies expressing the full FMRpolyG sequence. The difference of toxicity of the polyglycine stretch in isolation between cell culture and *Drosophila* is probably due to the longer time frame and in vivo nature of the *Drosophila* studies. Overall, these results demonstrate that expression of FMRpolyG is pathogenic, with its polyglycine stretch driving aggregation and with both polyglycine and its C terminus contributing to toxicity in vivo.

FMRpolyG Interacts with LAP2β and Alters the Nuclear Lamina {#sec2.6}
-----------------------------------------------------------

To identify FMRpolyG binding proteins, we performed a tandem tag purification of HA-FLAG-tagged FMRpolyG transfected into Neuro2A cells followed by nano-LC-MS/MS analysis of associated proteins. This approach identified various FMRpolyG-associated proteins ([Table S1](#mmc1){ref-type="supplementary-material"}), including Lap2β ([Figure 6](#fig6){ref-type="fig"}A). Lamina-associated polypeptide 2 (LAP) alpha and beta are two isoforms of the LAP2 protein that differ in their C-termini; these isoforms originate from alternative splicing of the *TMPO* pre-mRNA. LAP2α is diffusely localized in the nucleus, while LAP2β carries a transmembrane domain in its C terminus that anchors it to the inner nuclear membrane ([@bib15]). LAP2β interacts with lamin B1 and B2 and helps to organize these proteins near the nuclear inner membrane. Consequently, alteration of LAP2β results in disorganization of the nuclear lamina architecture ([@bib10], [@bib16]).

Co-immunoprecipitation studies confirmed the association of LAP2β with HA-FLAG-tagged FMRpolyG, but not with the polyglycine stretch in isolation ([Figure 6](#fig6){ref-type="fig"}B). Similar results were observed when a GFP tag was used instead of the double FLAG-HA tag ([Figure 6](#fig6){ref-type="fig"}C). An interaction between LAP2β and FMRpolyG raises questions of whether translation of the expanded CGG repeats in FXTAS may alter the localization or the function of LAP2β. Expression of FMRpolyG-GFP in primary cultures of cortical neurons from mouse embryo indicated that FMRpolyG recruits endogenous Lap2β in nuclear aggregates ([Figure 6](#fig6){ref-type="fig"}D). Similar results were observed in HEK293 cells and when the GFP was replaced by a smaller FLAG tag ([Figure S6](#mmc1){ref-type="supplementary-material"}A). In contrast, a construct containing only the polyglycine stretch of FMRpolyG did not alter Lap2β localization, suggesting that the C-terminal part of FMRpolyG is important for interaction and de-localization of LAP2β ([Figure 6](#fig6){ref-type="fig"}D). Immunohistochemistry assays confirmed that endogenous Lap2β localizes in nuclear aggregates in brain sections of the full 5′ UTR *FMR1* transgenic mice, unlike in mutant 5′ UTR mice ([Figure 6](#fig6){ref-type="fig"}E). These aggregates of Lap2β co-localized with FMRpolyG inclusions ([Figure 6](#fig6){ref-type="fig"}F). We next tried to confirm these results in brain sections of individuals with FXTAS. However, LAP2β immunohistochemistry was of poor quality on human autopsied material. We nevertheless observed some LAP2β aggregates in cerebellum sections as well as in the hippocampal area of FXTAS individuals ([Figures 6](#fig6){ref-type="fig"}G and [S6](#mmc1){ref-type="supplementary-material"}B). Furthermore, immunofluorescence assays indicated that LAP2β co-localized with FMRpolyG inclusions in individuals with FXTAS, but not in age-matched control individuals ([Figure 6](#fig6){ref-type="fig"}H).

Alteration of LAP2β results in disorganization of the nuclear lamina ([@bib16], [@bib10]). Thus, we next investigated the consequences of FMRpolyG expression on the architecture of the nuclear lamina. Expression of 99 CGG repeats embedded within the 5′ UTR of *FMR1* fused in the glycine frame with either a GFP or a FLAG tag in HEK293 cells resulted in disorganization of the nuclear lamina, as evidenced by alterations of the lamin B1 labeling ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Similarly, expression of FMRpolyG-GFP in primary cultures of mouse embryonic cortical neurons altered lamin B1 nuclear organization ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Furthermore, and as reported previously with lamin A ([@bib25]), the localization of lamin B1 was altered in brain sections of FXTAS compared to controls ([Figure S6](#mmc1){ref-type="supplementary-material"}E).

LAP2β and Nuclear Lamina Are Altered in Neurons Differentiated from FXTAS iPS Cells {#sec2.7}
-----------------------------------------------------------------------------------

Alterations of the nuclear lamina were observed in autopsied samples that may represent an end stage of the disease. To overcome this potential bias, we developed human induced pluripotent stem (iPS) cells derived from fibroblasts from two age-matched controls and three different FXTAS patients with expansion of 84, 90, and 99 CGG repeats. These iPS cells were differentiated into homogeneous populations of telencephalic neurons with no obvious difference of growth or differentiation between FXTAS and controls iPS cells ([Figure S7](#mmc1){ref-type="supplementary-material"}A). As observed previously ([@bib35]), expression of *FMR1* mRNA was increased 2- to 3-fold in differentiated neurons derived from FXTAS iPS cells compared to controls ([Figure S7](#mmc1){ref-type="supplementary-material"}B). This is consistent with the increased levels of *FMR1* mRNA observed in carriers of a CGG pre-mutation ([@bib50], [@bib51], [@bib34]).

Immunofluorescence assays detected accumulation of nuclear aggregates of FMRpolyG in FXTAS neurons, but not in control neurons ([Figure 7](#fig7){ref-type="fig"}A). FMRpolyG aggregates accumulated over time post-differentiation, with 5% to 10% of neurons exhibiting small FMRpolyG aggregates at 20 days of differentiation, while 20% to 30% of neurons present FMRpolyG nuclear aggregates after 40 days of differentiation ([Figure S7](#mmc1){ref-type="supplementary-material"}C). In contrast, RNA foci of expanded CGG repeats were rare or absent in FXTAS neurons at 40 days post-differentiation ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Importantly, immunofluorescence analysis revealed that endogenous LAP2β loses its normal localization and forms nuclear inclusions that co-localize with FMRpolyG in neurons differentiated from FXTAS iPS cells ([Figure 7](#fig7){ref-type="fig"}A). Furthermore, aggregation of LAP2β and FMRpolyG were associated with disorganization of the nuclear lamina structure, as shown by alteration of the lamin B1 labeling in FXTAS neurons ([Figure 7](#fig7){ref-type="fig"}B). In contrast, neurons differentiated from iPS cells of control individuals exhibited normal LAP2β and lamin B1 localization ([Figures 7](#fig7){ref-type="fig"}A and 7B).

Overexpression of LAP2 Rescues Neuronal Cell Death Caused by FMRpolyG {#sec2.8}
---------------------------------------------------------------------

Finally, LAP2β overexpression was sufficient to rescue the cell death induced by transfection of FMRpolyG-GFP in neuronal cells ([Figure 7](#fig7){ref-type="fig"}C). Consistent with LAP2β binding to the C-terminal part of the FMRpolyG protein, expression of LAP2β also rescued cell death caused by expression of the FMRpolyG C terminus in isolation ([Figure 7](#fig7){ref-type="fig"}C). As controls, expression of LAP2β had no effect on neuronal survival in control GFP-transfected cells or in neurons expressing the polyglycine fragment in isolation. Similar results were observed when the GFP was replaced by a smaller FLAG tag ([Figure S7](#mmc1){ref-type="supplementary-material"}D). Overall, these data suggest a mechanism by which FMRpolyG can elicit toxicity ([Figure 8](#fig8){ref-type="fig"}), and they provide an explanation for previously observed nuclear lamina disorganization in FXTAS patients ([@bib1], [@bib25], [@bib21]).

Discussion {#sec3}
==========

Previous studies have demonstrated that FXTAS is caused by expression of mutant RNAs containing expanded CGG repeats ([@bib54], [@bib29], [@bib1], [@bib20], [@bib11], [@bib22], [@bib23]). However, whether expanded CGG repeats are pathogenic through an RNA gain-of-function mechanism or through translation into a toxic protein was unclear. Using novel mouse models with or without FMRpolyG expression, our study suggests a direct role for FMRpolyG in CGG-repeat-associated toxicity. This study confirms in a mammalian system previous results obtained in *Drosophila* ([@bib53]). Moreover, we found that FMRpolyG disrupts nuclear lamina architecture through binding to the nuclear envelope protein LAP2β. These finding are reminiscent of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (ALS-FTD) in which expanded GGGGCC repeats in the *C9ORF72* gene ([@bib43], [@bib9]) are RAN translated into pathogenic di-peptide-containing proteins ([@bib2], [@bib37], [@bib58]) that disrupt nucleocytoplasmic transport ([@bib55], [@bib56], [@bib13], [@bib31]).

In contrast to the RAN translation of CAG expanded repeats in the polyalanine frame, which was shown to initiate within the expanded repeats ([@bib57]), our work confirms that expression of FMRpolyG depends largely on initiation at a near-cognate codon located upstream of the CGG repeats ([@bib53], [@bib33]). Moreover, we provide mass spectrometry data indicating that the N-terminal amino acid of FMRpolyG is a methionine in mammalian cells, suggesting a canonical mechanism of initiation with altered start-codon fidelity. Our data also suggest that expanded CGG repeats belong to a potential small ORF translated upstream of the main FMRP ORF. However, FMRpolyG is hardly detectable below 70 CGG repeats. This is consistent with the difficulties in detecting small proteins below 10 kDa, but also with the increased expression of mutant CGG RNA in carriers of pre-mutation over 70 CGG repeats ([@bib50], [@bib51], [@bib34]) and with the proposed increase in ribosomal stalling at a CGG hairpin structure, which would promote translation initiation to near-cognate codons located upstream of the CGG repeats ([@bib53], [@bib33]). Reduced expression of FMRpolyG below 70 CGG repeats may provide some molecular basis for the threshold of severity and incomplete penetrance observed in FXTAS, as most of pre-mutation alleles contain less than 70 CGG repeats (review in [@bib52]). We also noted that translation of the FMRpolyG uORF reduces the expression of FMRP; thus, expression of FMRpolyG may contribute to the decrease of FMRP expression observed in FXTAS individuals ([@bib50], [@bib51], [@bib34]). However, other mechanisms may also contribute to the decreased expression of FMRP in FXTAS, including the increased ribosome stalling observed with expanded CGG RNA hairpin structure ([@bib12], [@bib41]). Ribosome profiling and bioinformatics analyses reveal that upstream ORFs (uORFs) are common in mammalian mRNAs and can initiate at non-canonical codons ([@bib7], [@bib24], [@bib14], [@bib28]). Mutations in uORFs are known to cause human disease, mostly by altering the expression of their downstream ORFs (reviewed in [@bib4]). In contrast, we propose here that FXTAS is characterized by a mutation extending the length of a uORF and resulting in expression of a toxic, polyglycine-containing protein, FMRpolyG. This model is reminiscent of expansion of tri-nucleotide repeats in ORFs, resulting in expression of pathogenic polyglutamine- or polyalanine-containing proteins (reviewed in [@bib38]).

Of interest, a pathogenic mechanism in which expansion of nucleotide repeats into a uORF results in expression of a toxic protein may apply to other diseases. For example, aggregates of FMRpolyG were observed in ovarian stromal cells of a woman with Fragile-X-associated primary ovarian insufficiency (FXPOI), caused, like FXTAS, by expanded CGG repeats in the *FMR1* gene ([@bib6]). Similarly, it is striking to note that expanded GGGGCC repeats, which are located upstream of the *C9ORF72* ORF and are the main genetic cause of ALS-FTD, are in frame with an upstream, CTG near-cognate codon in a correct Kozac sequence (gctCTGg) to encode a glycine alanine-polypeptide, which is the most common dipeptide-repeat protein detected in individuals with ALS-FTD ([@bib36]). While hypothetical, extending further the FXTAS and fragile X model to *C9ORF72* might predict that long expansions of GGGGCC repeats in tissues prone to somatic expansions would be transcriptionally silent due to epigenetic modification of the promoter, while shorter expansions in tissues prone to repeat contraction would be transcribed and translated.

One of the main conclusions of this work is that mice expressing FMRpolyG develop a locomotor phenotype with reduced longevity, while mice expressing only the expanded CGG repeat RNA are indistinguishable from control mice. These results suggest that accumulation of RNA with expanded CGG repeats or RAN translation initiating within these repeats is not overly pathogenic in mice, at least in the time frame of our study. While informative on the pathogenicity of FMRpolyG, these mouse models present some limitations. Notably, our behavioral and locomotor investigations were limited to the first 3 months of life, because animals expressing FMRpolyG in the brain develop obesity and grow immobile at around 6 months of age. This is in contrast to an individual with FXTAS who do not develop morbid obesity. Furthermore, no FMRpolyG-expressing mice survived past 1 year of age, impairing our ability to observe potential neurodegeneration at later ages. As transgene expression is driven by an artificial promoter in these mice, it is likely that their premature death is due to a non-physiological level and/or distribution of transgene expression that may be unrelated to what occurs in FXTAS. Thus, analysis of potential Purkinje cell dropout and ataxia at old age will require specific expression of FMRpolyG in mouse cerebellum.

Direct comparison of these novel mice with previous models of FXTAS expressing either mRNA with 90 CGG repeats and FMRpolyG protein ([@bib54], [@bib20], [@bib23]) or only mRNA with ∼118 CGG repeats ([@bib11], [@bib42]) is difficult, as these mice either express endogenous levels of *FMR1* mRNA with knockin of the expanded CGG repeats into the endogenous *Fmr1* gene ([@bib54], [@bib11]) or express expanded repeats in more restricted brain regions than the mouse models reported here ([@bib20], [@bib23]). It is noteworthy that knockin mice with expanded CGG repeats, which do not express FMRpolyG due to presence of a stop codon located upstream of the CGG repeats ([@bib11], [@bib53]), exhibit some Purkinje cell dropout at 2 years of age but exhibit no ataxia or rotarod deficiency and only a mild behavioral phenotype with hyperactivity, reduced anxiety, and some subtle deficits in social interaction ([@bib11], [@bib42]). These behavioral alterations are similar to those observed in *Fmr1* knockout mouse models; this suggests that they might be caused, in part, by the reduced expression of FMRP observed in this CGG knockin mouse model ([@bib42]). In contrast, the mild Purkinje cell dropout observed at 2 years of age in that mouse model ([@bib11]) could be caused by expression of the mutant RNA containing expanded CGG repeats and/or RAN translation from these repeats. We failed to detect RNA foci of expanded CGG repeats or nuclear aggregates of FMRpolyA in our mouse models or in neurons from human iPS cells derived from individuals with FXTAS. However, this could originate from technical issues, notably a lack of sufficient sensitivity of our FISH probes of our FMRpolyA antibody. It is also possible that CGG RNA foci and FMRpolyA appear at a later stage of the disease. Thus, whether accumulation of CGG RNA and/or RAN translation of CGG repeats into FMRpolyA might contribute to pathogenicity in FXTAS remains an open question.

Finally, we found that toxicity of FMRpolyG is mediated at least in part through sequestration of the LAP2β protein into nuclear aggregates, leading to disruption of the nuclear lamina architecture and neuronal cell death. These data provide a molecular mechanism for the previously reported nuclear lamina disorganization in FXTAS ([@bib1], [@bib25], [@bib21]). However, the cell toxicity rescue observed upon overexpression of LAP2β may also originate from high levels of LAP2β blocking the interaction of FMRpolyG with various other proteins. Thus, it is possible that FMRpolyG mediates its toxic effects through more than one mechanism and/or protein partner. Notably, LAP2β regulates gene expression through association with various transcription factors as well as with DNA and with the DNA-binding protein BAF1 (barrier to auto-integration factor 1) protein ([@bib47]). It remains to be determined whether FMRpolyG alters this LAP2 transcriptional regulatory activity. Also, proteomic analysis indicates that FMRpolyG pulls down various other proteins, including cytoskeleton, mitochondrial, and proteasome proteins. Some of these proteins are good candidates to contribute to the mitochondrial alterations that have been observed in FXTAS ([@bib44], [@bib32], [@bib22]). Similarly, FMRpolyG appears critical for elicitation of ubiquitin proteasome impairment when expressed in cells or *Drosophila* ([@bib39]). Further investigations will be needed to test the potential pathological effect of FMRpolyG on mitochondria, protein degradation mechanisms, and cell cytoskeleton in FXTAS.

In conclusion, the *FMR1* gene encodes for at least two different proteins, FMRpolyG and FMRP, whose levels are inversely modulated by the size of the CGG repeat expansion and which are involved in two different genetic diseases, FXTAS and fragile X syndrome.

Experimental Procedures {#sec4}
=======================

Human Samples {#sec4.1}
-------------

All brain samples were obtained from the FXTAS brain repository at the UC Davis School of Medicine with the informed consent of individuals and were approved by the Institutional Review Board of the University of California, Davis. Patients have been described previously (Cases LR, 58-02-WD and 1007-05-HP from [@bib17] and [@bib40]). Fibroblasts of three FXTAS male individuals with confirmed pre-mutation of 84, 90, and 99 CGG repeats were obtained with the informed consent of individuals and approved by the Institutional Review Board of the Hospital La Pitié Salpêtrière.
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Document S1. Supplemental Experimental Procedures, Figures S1--S7, and Table S1Movie S1. Mice with Mutant *FMR1* 5′ UTRs Present Normal Locomotor Activity, Related to Figure 3Video recording of ledge test of 3-month-old bigenic CMV-cre/mutant *FMR1* 5′ UTR transgenic mice indicates normal locomotor function and equilibrium.Movie S2. Mice Expressing FMRpolyG Present Gait Instability, Related to Figure 3Video recording of ledge test of 3-month-old bigenic CMV-cre/full-length FMR1 5′ UTR transgenic mice indicates that FMRpolyG-expressing mice present some gait instability and increased foot slippage.Movie S3. Time-Lapse Recording of Neurons Expressing GFP, Related to Figure 5A 24-hr recording of primary cultures of E18 mouse cortical neurons transfected with RFP and with control GFP.Movie S4. Time-Lapse Recording of Neurons Expressing FMRpolyG-GFP, Related to Figure 5A 24-hr recording of primary cultures of E18 mouse cortical neurons transfected with RFP and ATG-driven FMRpolyG-GFP full-length. Expression of FMRpolyG is toxic and leads to neuronal cell death.Movie S5. Time-Lapse Recording of Neurons Expressing Polyglycine-GFP, Related to Figure 5A 24 hr recording of primary cultures of E18 mouse cortical neurons transfected with RFP and with ATG-driven polyglycine stretch (99×) with FMRpolyG C terminus deleted. Expression of the polyglycine leads to aggregate formation.Movie S6. Time-Lapse Recording of Neurons Expressing FMRpolyG C-Terminal Part-GFP, Related to Figure 5A 24 hr recording of primary cultures of E18 mouse cortical neurons transfected with RFP and with the ATG-driven C-terminal part of FMRpolyG (the last 42 amino acids) fused to the GFP. Expression of FMRpolyG C terminus leads to neuronal cell death.Document S2. Article plus Supplemental Information
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![Translation of CGG Repeats Initiates at an Upstream Near-Cognate Codon\
(A) Immunoblotting against GFP on the soluble lysate fraction of HeLa cells transfected for 24 hr with expanded CGG repeats embedded, or not, in the 5′ UTR of *FMR1* and fused in all three possible frames with the GFP deleted of its ATG.\
(B) Upper, schemes of the *FMR1* 5′ UTR deletion constructs tested. Middle, immunoblotting against GFP on the soluble lysate fraction of HeLa cells transfected for 24 hr with mutants of *FMR1* 5′ UTR containing expanded CGG repeats fused to the GFP in the glycine frame. Lower, quantification of FMRpolyG-GFP expression reported to GAPDH.\
(C) LC-MS/MS spectra of the N-terminal part of the immunoprecipitated and trypsin-digested protein translated from expanded CGG embedded in the 5′ UTR of *FMR1*.\
(D) Scheme and partial nucleotide sequence of human *FMR1* exons 1 and 2. Amino acid sequence of *FMR1* uORF translated into FMRpolyG is indicated in red. Amino acid sequence of the beginning of the FMRP ORF is indicated in green.\
Error bars indicate SEM of three independent transfections. Student's t test, ^∗∗∗^ indicates p \< 0.001.](gr1){#fig1}

![A Minimum of 60 Expanded CGG Repeats Is Required to Detect FMRpolyG\
(A) Upper, immunoblotting against the FLAG tag on the soluble lysate fraction of HeLa cells transfected for 24 hr with various lengths of expanded CGG repeats embedded in the 5′ UTR of *FMR1* and fused in the glycine frame with the FLAG tag. Middle, control immunoblotting against GAPDH. Lower, quantification of FMRpolyG-FLAG levels reported to GAPDH.\
(B) Identical to (A), but with CGG repeats embedded in the 5′ UTR of *FMR1* fused in the glycine frame with a GFP tag instead of a FLAG tag.\
(C) Left, schemes of the 5′ UTR of *FMR1* constructs with ACG mutations. FMRpolyG uORF is FLAG-tagged in the glycine frame, while FMRP ORF is GFP-tagged. Right, upper, and middle, immunoblotting against FLAG, GFP, and GAPDH on the soluble lysate fraction of HeLa cells transfected for 24 hr with mutants of the 5′ UTR of *FMR1*; expanded CGG repeats are fused to the FLAG tag in the glycine frame, while the downstream FMRP ORF is fused to the GFP. Right lower, quantification of FMRpolyG-FLAG and FMRP-GFP levels reported to GAPDH.\
(D) Immunofluorescence against the FMRpolyG N terminus and ubiquitin on brain sections (hippocampal area) of FXTAS or control individuals. Scale bars, 10 μm. Nuclei were counter-stained with DAPI.\
(E) Immunoblotting against the FMRpolyG N terminus of insoluble fraction of brain lysate (cerebellum area) of FXTAS and age-matched individuals.\
The numbers of expanded CGG in *FMR1* are indicated as \# CGG. Error bars indicate SEM of three independent transfections. Student's t test, ^∗^ indicates p \< 0.05, ^∗∗∗^ indicates p \< 0.001.](gr2){#fig2}

![Expression of FMRpolyG Is Pathogenic in Mice\
(A) Schemes of the mouse transgene constructs.\
(B) Quantitative RT-PCR analysis of transgene expression relative to the *RplpO* mRNA in different brain areas and tissues of 6-month-old control (n = 3), bigenic CMV-cre/full-length (n = 3), or mutant (n = 3) *FMR1* 5′ UTR transgenic mice.\
(C) Immunohistochemistry against FMRpolyG N terminus of cerebellum and hippocampus areas of 6-month-old bigenic CMV-cre/full-length or mutant *FMR1* 5′ UTR transgenic mice. Scale bars, 10 μm. Sections were counter-stained with Nissl staining.\
(D) Immunofluorescence against FMRpolyG N terminus and ubiquitin on cerebellum areas of 6-month-old bigenic CMV-cre/full-length or mutant *FMR1* 5′ UTR transgenic mice. Scale bars, 10 μm. Nuclei were counter-stained with DAPI.\
(E) Rotarod test: the time before falling from a rotating rod of 3-month-old control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9) *FMR1* 5′ UTR transgenic male mice.\
(F) String test: the time to gain hindlimb traction for forelimb-hanging 3-month-old control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9) *FMR1* 5′ UTR transgenic male mice.\
(G) Grip test: the maximal force relative to mouse body weight exerted to release 3-month-old control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9) *FMR1* 5′ UTR transgenic male mice holding a grid with their forepaws.\
(H) Open field: number of rears during 5 min observation in open field of 3-month-old control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9) *FMR1* 5′ UTR transgenic male mice.\
(I) Body weight of 2-, 4-, and 6-month-old control (n = 6), bigenic CMV-cre/full-length (n = 6), or mutant (n = 6) *FMR1* 5′ UTR transgenic male mice.\
(J) Left, immunofluorescence labeling of calbindin of cerebellum sections of 9-month-old bigenic CMV-cre/full-length or mutant *FMR1* 5′ UTR transgenic mice. Scale bars, 10 μm. Nuclei were counter-stained with DAPI. Right, quantification of Purkinje cells (n = 100) in cerebellum sections of 9-month-old bigenic CMV-cre/full-length (n = 3) or mutant *FMR1* 5′ UTR (n = 3) transgenic mice.\
(K) Kaplan-Meier survival curve of control (n = 15), bigenic CMV-cre/full-length (n = 15), or mutant (n = 15) *FMR1* 5′ UTR male and female transgenic mice.\
Error bars indicate SEM. Student's t test, ^∗^ indicates p \< 0.05, ^∗∗^ indicates p \< 0.01 and ^∗∗∗^ indicates p \< 0.001.](gr3){#fig3}

![Neuronal Expression of FMRpolyG Is Pathogenic in Mice\
(A) Schemes of the mouse transgene constructs.\
(B) Quantitative RT-PCR analysis of transgene expression relative to the *RplpO* mRNA in different tissues of 6-month-old control (n = 3), bigenic CMV-cre/full-length *FMR1* 5′ UTR (n = 3), or bigenic Nestin-cre full-length *FMR1* 5′ UTR (n = 3) mice.\
(C) Immunohistochemistry against FMRpolyG N terminus in the cerebellum, hippocampus, and hypothalamus of 6-month-old bigenic Nestin-cre/full-length *FMR1* 5′ UTR mice. Scale bars, 10 μm. Sections were counter-stained with H&E staining.\
(D) Rotarod test: time before falling of 3-month-old control (n = 6) or bigenic Nestin-cre/full-length *FMR1* 5′ UTR (n = 6) male mice.\
(E) Left, immunohistochemistry against calbindin of cerebellum sections of 10-month-old control or bigenic Nestin-cre/full-length *FMR1* 5′ UTR mice. Scale bars, 10 μm. Sections were counter-stained with H&E staining. Right, quantification of Purkinje cells (n = 50) in cerebellum sections of 10-month-old control (n = 3) or bigenic Nestin-cre/full-length *FMR1* 5′ UTR (n = 3) mice.\
(F) Immunohistochemistry against Gfap of hippocampal sections of 10-month-old control or bigenic Nestin-cre/full-length *FMR1* 5′ UTR mice.\
Scale bars, 50 μm. Sections were counter-stained with H&E staining.\
(G) Representative image of 8-month-old control or bigenic Nestin-cre/full-length *FMR1* 5′ UTR mice.\
(H) Kaplan-Meier survival curves of control (n = 10) or bigenic Nestin-cre/full-length *FMR1* 5′ UTR (n = 10) male and female mice.\
Error bars indicate SEM. Student's t test, ^∗^ indicates p \< 0.05, ^∗∗^ indicates p \< 0.01.](gr4){#fig4}

![FMRpolyG Toxicity Is Influenced by Its Carboxyl Terminus\
(A) Immunofluorescence against FMRpolyG N terminus and Lmnb1 in primary cultures of E18 mouse cortical neurons transfected for the indicated time period with expanded CGG repeats embedded within the 5′ UTR of *FMR1* and fused to the GFP in the glycine frame. Scale bars, 10 μm. Nuclei were counter-stained with DAPI.\
(B) Left, representative images of primary cultures of E18 mouse cortical neurons transfected with GFP or ATG-driven FMRpolyG-GFP full-length or mutants. Scale bars, 10 μm. Nuclei were counter-stained with DAPI. Right, schemes of the mutant constructs of FMRpolyG-GFP. The Nter construct corresponds to the N-terminal part of FMRpolyG including its polyglycine repeats fused to the GFP. The Cter construct corresponds to the last 42 amino acids of FMRpolyG fused to the GFP. Lower, quantification of neuronal cell viability of GFP-positive (n = 100 cells, three independent transfections) transfected E18 mouse cortical neurons.\
(C) Progeny eclosion ratio (n = 100, three independent crosses) of *Drosophila* ubiquitously expressing FMRpolyG, either full-length or deleted of its C terminus compared to control driver line (*Actin5C-Gal4/+*).\
(D) Kaplan-Meier survival curve of *Drosophila* expressing FMRpolyG full-length or deleted of its C terminus compared to control driver line (*Tub5-Gal4/+*).\
Error bars indicate SEM. Student's t test, ^∗^ indicates p \< 0.05, ^∗∗∗^ indicates p \< 0.001.](gr5){#fig5}

![FMRpolyG Interacts with LAP2β and Alters Its Nuclear Localization\
(A) Silver staining of proteins captured through consecutive anti-FLAG and anti-HA affinity purification steps from N2A cells transfected for 24 hr with ATG-driven FLAG-HA-tagged FMRpolyG, either full-length or deleted of its C terminus.\
(B) Immunoblotting against endogenous Lap2β protein of tandem-tag purified proteins from N2A cells transfected for 24 hr with ATG-driven FLAG-HA-tagged FMRpolyG, either full-length or deleted of its C terminus.\
(C) Immunoblotting against the HA or GFP tags of HA-tagged immunoprecipitated proteins from the soluble lysate fraction of N2A cells transfected for 24 hr with HA-LAP2β and ATG-driven FMRpolyG-GFP, either full-length or deleted of its N or C terminus.\
(D) Left, GFP fluorescence and immunofluorescence against endogenous Lap2β in primary cultures of E18 mouse cortical neurons transfected with expanded CGG repeats embedded within the 5′ UTR of *FMR1* either full-length or deleted of FMRpolyG C terminus and fused to the GFP in the glycine frame. Nuclei were counterstained with DAPI. Right, quantification of co-localization of Lap2β with GFP inclusions in transfected E18 mouse cortical neurons (n = 100 neurons, three independent transfections).\
(E) Immunohistochemistry against Lap2β of cerebellum, hippocampal and hypothalamic areas of 9-month-old bigenic CMV-cre/full-length or mutant *FMR1* 5′ UTR transgenic mice. Sections were counter-stained with H&E staining.\
(F) Left, immunofluorescence against FMRpolyG N terminus and Lap2β on hippocampal areas of 9-month-old bigenic CMV-cre/full-length or mutant *FMR1* 5′ UTR transgenic mice. Nuclei were counter-stained with DAPI. Right, quantification of co-localization of Lap2β with FMRpolyG in bigenic CMV-cre/full-length or mutant *FMR1* 5′ UTR transgenic mice (n = 50 neurons, three mice).\
(G) Immunohistochemistry against LAP2β of cerebellum areas of FXTAS individual or age-matched control. Sections were counter-stained with H&E staining.\
(H) Immunofluorescence against FMRpolyG N terminus and LAP2β on brain sections (hippocampal area) of FXTAS patients or age-matched controls. Nuclei were counter-stained with DAPI.\
Scale bars, 10 μm. Error bars indicate SEM. Student's t test, ^∗∗∗^ indicates p \< 0.001.](gr6){#fig6}

![LAP2β Rescues Neuronal Cell Death Induced by FMRpolyG\
(A) Upper, immunofluorescence against FMRpolyG N terminus and LAP2β on neuronal cultures differentiated 40 days from iPS cells of FXTAs patients or control individuals. Lower, quantification of LAP2β co-localization with FMRpolyG in neurons from iPSC of FXTAS and control individuals (n = 100 neurons, three independent cultures).\
(B) Upper, immunofluorescence against FMRpolyG N terminus and LMNB1 on neuronal cultures differentiated 40 days from iPS cells of FXTAs patients or control individuals. Lower, quantification of lamin B1 alteration in FMRpolyG-positive cells in neurons from iPSC of FXTAS and control individuals (n = 100 neurons, three independent cultures).\
(C) Cell viability of neuronal N2A cells transfected (n = 3 transfections) with ATG-driven FMRpolyG-GFP either full-length or deleted of its N or C terminus and with a plasmid expressing RFP as control or Ha-tagged LAP2β.\
Error bars indicate SEM. Student's t test, ^∗∗∗^ indicates p \< 0.001.](gr7){#fig7}

![A Working Model for Pathogenicity in FXTAS\
Expanded CGG repeats are translated into a polyglycine-containing protein, FMRpolyG, through initiation to a non-canonical ACG codon located upstream of the CGG repeats. In FXTAS, higher expression of *FMR1* mRNA and increased translation and stability of the expanded CGG repeats result in accumulation of FMRpolyG in nuclear aggregates that sequester the LAP2β protein and alter the nuclear lamina architecture.](gr8){#fig8}
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